 | • レポートコード：MRC2302E0136 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、220ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療 |
| Single User（1名利用、印刷可） | ￥732,452 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,472,452 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本調査レポートは、2021年に1,692.14百万ドルであった世界の受胎＆妊娠迅速検査市場規模が、2022年に1,818.12百万ドルになり、2027年まで年平均7.62%で成長して2,629.33百万ドルに達すると予測しています。本レポートでは、受胎＆妊娠迅速検査の世界市場について調査し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、デバイス種類別（デジタルデバイス、ラインインジケータデバイス）分析、検査種類別（FSH尿検査、LH尿検査、hCG血液検査、hCG尿検査）分析、種類別（受胎能迅速検査キット、妊娠迅速診断キット）、流通チャネル別（ドラッグストア、婦人科＆不妊治療クリニック、ハイパーマーケット＆スーパーマーケット、オンライン、薬局）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などの項目を掲載しています。また、本書には、About, Inc.、Atlas Medical International Inc、bioMérieux S.A.、Church & Dwight Co., Inc.、EGENS GROUP、Eurofins Scientific SE、Everlywell, Inc.、Expedient Healthcare Marketing Private Limited、F6S Network Limited、Genea Limited、General Electric Companyなどの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の受胎＆妊娠迅速検査市場規模：デバイス種類別 - デジタルデバイスの市場規模 - ラインインジケータデバイスの市場規模 ・世界の受胎＆妊娠迅速検査市場規模：検査種類別 - FSH尿検査の市場規模 - LH尿検査の市場規模 - hCG血液検査の市場規模 - hCG尿検査の市場規模 ・世界の受胎＆妊娠迅速検査市場規模：種類別 - 受胎能迅速検査キットの市場規模 - 妊娠迅速診断キットの市場規模 ・世界の受胎＆妊娠迅速検査市場規模：流通チャネル別 - ドラッグストアチャネルの市場規模 - 婦人科＆不妊治療クリニックチャネルの市場規模 - ハイパーマーケット＆スーパーマーケットチャネルの市場規模 - オンラインチャネルの市場規模 - 薬局チャネルの市場規模 ・世界の受胎＆妊娠迅速検査市場規模：地域別 - 南北アメリカの受胎＆妊娠迅速検査市場規模 アメリカの受胎＆妊娠迅速検査市場規模 カナダの受胎＆妊娠迅速検査市場規模 ブラジルの受胎＆妊娠迅速検査市場規模 ... - アジア太平洋の受胎＆妊娠迅速検査市場規模 日本の受胎＆妊娠迅速検査市場規模 中国の受胎＆妊娠迅速検査市場規模 インドの受胎＆妊娠迅速検査市場規模 韓国の受胎＆妊娠迅速検査市場規模 台湾の受胎＆妊娠迅速検査市場規模 ... -ヨーロッパ/中東/アフリカの受胎＆妊娠迅速検査市場規模 イギリスの受胎＆妊娠迅速検査市場規模 ドイツの受胎＆妊娠迅速検査市場規模 フランスの受胎＆妊娠迅速検査市場規模 ロシアの受胎＆妊娠迅速検査市場規模 ... -その他地域の受胎＆妊娠迅速検査市場規模 ・競争状況 ・企業情報 |
The Global Female Fertility & Pregnancy Rapid Test Market size was estimated at USD 1,692.14 million in 2021 and expected to reach USD 1,818.12 million in 2022, and is projected to grow at a CAGR 7.62% to reach USD 2,629.33 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Female Fertility & Pregnancy Rapid Test to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Device Type, the market was studied across Digital Devices and Line-indicator Devices.
Based on Test Type, the market was studied across FSH Urine Test, LH Urine Test, hCG Blood Test, and hCG Urine Test.
Based on Type, the market was studied across Fertility Rapid Test Kits and Pregnancy Rapid Test Kits.
Based on Distribution Channel, the market was studied across Drugstores, Gynecology & fertility clinics, Hypermarkets & supermarkets, Online, and Pharmacies.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Female Fertility & Pregnancy Rapid Test market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Female Fertility & Pregnancy Rapid Test Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Female Fertility & Pregnancy Rapid Test Market, including About, Inc., Atlas Medical International Inc, bioMérieux S.A., Church & Dwight Co., Inc., EGENS GROUP, Eurofins Scientific SE, Everlywell, Inc., Expedient Healthcare Marketing Private Limited, F6S Network Limited, Genea Limited, General Electric Company, Geratherm Medical AG, Novartis AG, Partners-Lab, Prestige Consumer Healthcare Inc., Progyny, Inc., Quidel Corporation, SPD Swiss Precision Diagnostics GmBH, Swiss Precision Diagnostics GmbH;, and Thermo Fisher Scientific Inc.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Female Fertility & Pregnancy Rapid Test Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Female Fertility & Pregnancy Rapid Test Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Female Fertility & Pregnancy Rapid Test Market?
4. What is the competitive strategic window for opportunities in the Global Female Fertility & Pregnancy Rapid Test Market?
5. What are the technology trends and regulatory frameworks in the Global Female Fertility & Pregnancy Rapid Test Market?
6. What is the market share of the leading vendors in the Global Female Fertility & Pregnancy Rapid Test Market?
7. What modes and strategic moves are considered suitable for entering the Global Female Fertility & Pregnancy Rapid Test Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising demand for the quick and self-contained test than the time-consuming lab-based test
5.1.1.2. Growing incidence of infertility and gynecological disorders
5.1.2. Restraints
5.1.2.1. Absurdity of choice due to the availability of too many options
5.1.2.2. Controversies and device-related issues
5.1.3. Opportunities
5.1.3.1. Technological advancements and attractive product features such as smartphone app connectivity
5.1.3.2. Increasing awareness about the kits in the developing economies
5.1.4. Challenges
5.1.4.1. Availability of alternative diagnostic tests, such as blood test and reagent-based laboratory test with fewer chances of error
5.2. Cumulative Impact of COVID-19
6. Female Fertility & Pregnancy Rapid Test Market, by Device Type
6.1. Introduction
6.2. Digital Devices
6.3. Line-indicator Devices
7. Female Fertility & Pregnancy Rapid Test Market, by Test Type
7.1. Introduction
7.2. FSH Urine Test
7.3. LH Urine Test
7.4. hCG Blood Test
7.5. hCG Urine Test
8. Female Fertility & Pregnancy Rapid Test Market, by Type
8.1. Introduction
8.2. Fertility Rapid Test Kits
8.3. Pregnancy Rapid Test Kits
9. Female Fertility & Pregnancy Rapid Test Market, by Distribution Channel
9.1. Introduction
9.2. Drugstores
9.3. Gynecology & fertility clinics
9.4. Hypermarkets & supermarkets
9.5. Online
9.6. Pharmacies
10. Americas Female Fertility & Pregnancy Rapid Test Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Female Fertility & Pregnancy Rapid Test Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Female Fertility & Pregnancy Rapid Test Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis, By Key Player
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion
14. Company Usability Profiles
14.1. About, Inc.
14.1.1. Business Overview
14.1.2. Key Executives
14.1.3. Product & Services
14.2. Atlas Medical International Inc
14.2.1. Business Overview
14.2.2. Key Executives
14.2.3. Product & Services
14.3. bioMérieux S.A.
14.3.1. Business Overview
14.3.2. Key Executives
14.3.3. Product & Services
14.4. Church & Dwight Co., Inc.
14.4.1. Business Overview
14.4.2. Key Executives
14.4.3. Product & Services
14.5. EGENS GROUP
14.5.1. Business Overview
14.5.2. Key Executives
14.5.3. Product & Services
14.6. Eurofins Scientific SE
14.6.1. Business Overview
14.6.2. Key Executives
14.6.3. Product & Services
14.7. Everlywell, Inc.
14.7.1. Business Overview
14.7.2. Key Executives
14.7.3. Product & Services
14.8. Expedient Healthcare Marketing Private Limited
14.8.1. Business Overview
14.8.2. Key Executives
14.8.3. Product & Services
14.9. F6S Network Limited
14.9.1. Business Overview
14.9.2. Key Executives
14.9.3. Product & Services
14.10. Genea Limited
14.10.1. Business Overview
14.10.2. Key Executives
14.10.3. Product & Services
14.11. General Electric Company
14.11.1. Business Overview
14.11.2. Key Executives
14.11.3. Product & Services
14.12. Geratherm Medical AG
14.12.1. Business Overview
14.12.2. Key Executives
14.12.3. Product & Services
14.13. Novartis AG
14.13.1. Business Overview
14.13.2. Key Executives
14.13.3. Product & Services
14.14. Partners-Lab
14.14.1. Business Overview
14.14.2. Key Executives
14.14.3. Product & Services
14.15. Prestige Consumer Healthcare Inc.
14.15.1. Business Overview
14.15.2. Key Executives
14.15.3. Product & Services
14.16. Progyny, Inc.
14.16.1. Business Overview
14.16.2. Key Executives
14.16.3. Product & Services
14.17. Quidel Corporation
14.17.1. Business Overview
14.17.2. Key Executives
14.17.3. Product & Services
14.18. SPD Swiss Precision Diagnostics GmBH
14.18.1. Business Overview
14.18.2. Key Executives
14.18.3. Product & Services
14.19. Swiss Precision Diagnostics GmbH;
14.19.1. Business Overview
14.19.2. Key Executives
14.19.3. Product & Services
14.20. Thermo Fisher Scientific Inc
14.20.1. Business Overview
14.20.2. Key Executives
14.20.3. Product & Services
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing